Antenatal corticosteroids and newborn screen for congenital adrenal hyperplasia

Archives of Pediatrics and Adolescent Medicine

Volumn 155, Issue 9, 2001, Pages 1038-1042

  King, Jennifer L ^a   Naber, John M ^b   Hopkin, Robert J ^c   Repaske, David R ^c   Bailey, Laurie ^c   Leslie, Nancy D ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b Newborn Screening Program   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROXYPROGESTERONE;

ARTICLE; CONGENITAL ADRENAL HYPERPLASIA; FETUS LUNG MATURATION; FLUOROIMMUNOASSAY; HORMONE BLOOD LEVEL; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SCREENING; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0034846266     PISSN: 10724710     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpedi.155.9.1038     Document Type: Article

References (26)

1. Current status of neonatal screening for congenital adrenal hyperplasia
2. Congenital adrenal hyperplasia (CAH): The place for prenatal treatment and neonatal screening
3. Molecular and clinical advances in congenital adrenal hyperplasia
4. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia
5. Steroid disorders in children: Congenital adrenal hyperplasia and apparent mineralocorticoid excess
6. Delayed diagnosis in congenital adrenal hyperplasia
7. Newborn screening for congenital adrenal hyperplasia in New Zealand
8. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder
9. Microfilter paper method for 17-hydroxyprogesterone radioimmunoassay: Its application for rapid screening for congenital adrenal hyperplasia
10. Serving the family from birth to the medical home: Newborn screening: A blueprint for the future - A call for a national agenda on state newborn screening programs
11. Effect of corticosteroids for fetal maturation on perinatal outcomes: National Institutes of Health Consensus Development Conference, February 28-March 2, 1994
12. Congenital adrenal hyperplasia
13. Screening for congenital adrenal hyperplasia: The Delfia screening test overestimates serum 17-hydroxyprogesterone in preterm infants
14. Effect of newborn screening for congenital adrenal hyperplasia
15. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels
16. Antenatal steroids and neonatal outcomes in controlled clinical trials of surfactant replacement
17. Methods to encourage the use of antenatal corticosteroid therapy for fetal maturation
18. Practice variation in the use of corticosteroids: A comparison of eight data sets
19. Neonatal effects and serum cortisol levels after multiple courses of maternal corticosteroids
20. Antenatal glucocorticoids modulate the amplitude of pulsatile cortisol secretion in premature neonates
21. Maternal glucocorticoid in unplanned premature labor: Controlled study on the effects of betamethasone phosphate on the phospholipids of the gastric aspirate and on the adrenal cortical function of the newborn infant
22. Multiple courses of betamethasone to enhance fetal lung maturation do not suppress neonatal adrenal response
23. Antenatal betamethasone therapy: Effects on maternal, fetal, and neonatal mineralocorticoids, glucocorticoids, and progestins
24. Who gets missed: Coverage in a provincial newborn screening program for metabolic disease
25. Delay in diagnosis of congenital adrenal hyperplasia in an acutely ill infant